Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Oral Fluid Swab

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 2/3 (1)

Trial Status

Completed1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT04061382CompletedPrimary

Sero-epidemiological Survey of England in 2019/2020 - COVID-19

NCT02858570Phase 2/3UnknownPrimary

Conjugate Vaccine Against Meningococcus C a Brazilian Project

Showing all 2 trials

Research Network

Common Treatments

  • Oral Fluid Swab1
  • Combined Crm1971
  • Venepuncture1
  • Menccbio Vaccine1

Active Sponsors

  • University of Oxford1
  • The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)1

Top Investigators

Related Conditions

  • Covid191
  • Diphtheria1

Activity Timeline